Imatinib mesylate in patients with various types of malignancies involving activated tyrosine kinase enzymes.

Trial Profile

Imatinib mesylate in patients with various types of malignancies involving activated tyrosine kinase enzymes.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Imatinib (Primary)
  • Indications Cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 30 Apr 2012 Planned end date changed from 1 Jul 2011 to 1 Apr 2012 as reported by ClinicalTrials.gov.
    • 01 Jan 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 29 Jun 2011 Planned End Date changed from 1 Jun 2011 to 1 Jul 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top